Improved tonsillar disposition of azithromycin following a 3-day oral treatment with 20 mg kg-1 in paediatric patients

Pharmacological Research

Volumn 46, Issue 1, 2002, Pages 95-100

  Baschiera, Fabio ^a   Fornai, Matteo ^a   Lazzeri, Gloria ^a   Blandizzi, Corrado ^a   Bruschini, Paolo ^b   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Azithromycin; Macrolides; Paediatric patient; Pharmacokinetics; Tonsil

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN;

ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG DETERMINATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TONSIL; TONSIL DISEASE; TONSILLECTOMY; UPPER RESPIRATORY TRACT;

EID: 0036417294     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00042-7     Document Type: Article

References (25)

1. Hoepelman IM, Schneider ME. Azithromycin: The first of the tissue-selective azalides. Int J Antimicrob Agents 1995; 5: 145-67.
2. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother 1993; 31(Suppl E): 39-50.
3. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob Agents Chemother 1987; 31: 1939-47.
4. Langtry HD, Balfour JA. Azithromycin: A review of its use in paediatric infectious diseases. Drugs 1998; 56: 273-97.
5. Foulds GK, Chan H, Johnson JT, Shepard RM, Johnson RB. Concentrations of azithromycin in human tonsillar tissue. Eur J Clin Microbiol Infect Dis 1991; 10: 853-6.
6. Vaudaux BP, Cherpillod J, Dayer P. Concentrations of azithromycin in tonsillar and/or adenoid tissue from paediatric patients. J Antimicrob Chemother 1996; 37(Suppl C): 45-51.
7. Dunn CJ, Barradell LB. Azithromycin: A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996; 51: 483-505.
8. Pacifico L, Scopetti F, Ranucci A, Pataracchia M, Savignoni F, Chiesa C. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrob Agents Chemother 1996; 40: 1005-8.
9. Cremer J, Wallrauch C, Milatovic D, Braveny I. Azithromycin versus cefaclor in the treatment of paediatric patients with acute group A beta-hemolytic streptococcal tonsillopharyngitis. Eur J Clin Microbiol Infect Dis 1998; 17: 235-9.
10. Amsden GW. Advanced-generation macrolides: Tissue-directed antibiotics. Int J Antimicrob Agents 2001; 18(Suppl 1): S11-5.
11. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanisms of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277-82.
12. Fietta A, Merlini C, Gialdroni Grassi G. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. J Chemother 1997; 9: 23-31.
13. Hand WL, Hand DL. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents 2001; 18: 419-25.
14. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991; 91(Suppl 3A): 5S-11S.
15. Varaldo PE, Debbia EA, Nicoletti G, Pavesio D, Ripa S, Schito GC, Tempera G, and the Artemis-Italy Study Group. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: Influence of macrolide resistance on clinical and microbiological outcomes. Clin Infect Dis 1999; 29: 869-73.
16. Giovanetti E, Montanari MP, Mingoia M, Varaldo PE. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains. Antimicrob Agents Chemother 1999; 43: 1935-40.
17. Van Bambeke F, Tulkens PM. Macrolides: Pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001; 18: S17-23.
18. Sastre-Toraño J, Guchelaar HJ. Quantitative determination of the macrolide antibiotics erythromycin, roxithromycin, azitromycin and clarithromycin in human serum by high-performance liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection. J Chromatogr B 1998; 720: 89-97.
19. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997; 16: 438-43.
20. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents and Chemother 1990; 34: 1056-60.
21. Pechère JC. Macrolide resistance mechanisms in Gram-positive cocci. Int J Antimicrob Agents 2001; 18: S25-8.
22. Savolainen S, Männistö PT, Gordin A, Antikainen R, Haataja H, Tuominen RK, Ylikoski J. Tonsillar penetration of erythromycin and its 2′-acetyl ester in patients with chronic tonsillitis. J Antimicrob Chemother 1988; 21(Suppl D): 73-84.
23. Galioto GB, Mevio E, Galioto EP, Zanuso G, Lepore AM. Concentrations of flurithromycin in serum and tonsils. Int J Clin Pharmacol Ther Toxicol 1989; 27: 126-8.
24. Benson JM, Arnold JJ, Manning SC, Coleman DL, Sides GD, Conforti PM, Lemon E, Watkins VS. Tonsillar tissue penetration of dirithromycin after multiple doses. J Clin Pharmacol 1996; 36: 832-7.
25. Fraschini F, Scaglione F, Pintucci G, Maccarinelli G, Dugnani S, Demartini G. The diffusion of clarithromycin and roxithromycin into nasal mucosa tonsil and lung in humans. J Antimicrob Chemother 1991; 27(Suppl A): 61-5.